“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z

Vijay Pande, the former head of Andreessen Horowitz's biotech division, has fundamentally shifted his investment philosophy after leaving the firm's $4 billion practice to launch VZVC, a significantly smaller, AI-focused venture fund. This transition reflects a broader transformation in how biological sciences are being approached and funded in the modern era.

Pande's departure from a16z marked a significant pivot in biotech investing strategy. Rather than maintaining the high-volume approach characteristic of larger venture firms, VZVC operates with a distinctly different mandate. As Pande emphasizes, the new fund is "not doing 30 bets a year," indicating a preference for selective, deeper investments rather than portfolio-spreading strategies. This approach aligns with his belief that biology is transitioning from a "discovery" science—characterized by broad exploration and unpredictability—to an "engineering" discipline, where systematic methodology and AI-driven approaches yield more predictable outcomes.

• AI Integration: The shift toward AI-native biotech investing suggests that machine learning and computational tools are becoming essential rather than supplementary to drug development
• Clinical Trial Economics: Despite technological advances, clinical trials remain prohibitively expensive, continuing to present a major bottleneck in bringing innovations to market
• Open Science Models: Pande advocates for more transparent, shared approaches to biological research, potentially reducing redundancy and accelerating discovery
• Smaller Funds as Specialists: Nimble, focused funds may outperform large-scale venture firms in specialized domains by enabling deeper expertise and closer collaboration
• Valuation Pressure: This strategy shift may signal changing expectations about startup valuations and return profiles in biotech

Pande's strategic repositioning represents a maturation in biotech venture capital. As artificial intelligence becomes increasingly central to biological research, the industry is recognizing that success requires specialized expertise rather than broad portfolio coverage. His emphasis on treating biology as an engineering challenge—rather than pure discovery—suggests we're entering a new era where computational approaches, systematic methodology, and targeted investment will drive meaningful progress in drug development and biologics.